Application and Research Progress of Selinexor in Hematologic Tumors Other Than Multiple Myeloma——Review
10.19746/j.cnki.issn1009-2137.2024.04.049
- VernacularTitle:塞利尼索在非多发性骨髓瘤血液肿瘤中的应用及研究进展
- Author:
Zhi-Wen XIAO
1
;
Ling QI
;
Fei LI
Author Information
1. 南昌大学第一附属医院血液病诊治中心;江西省血液病临床医学研究中心;南昌大学淋巴肿瘤疾病研究所,江西南昌 330006
- Keywords:
selinexor;
leukemia;
non-Hodgkin lymphoma;
myelodysplastic syndrome;
myeloproliferative neoplasm
- From:
Journal of Experimental Hematology
2024;32(4):1295-1299
- CountryChina
- Language:Chinese
-
Abstract:
Exportin-1(XPO1)is a major transporter for hundreds of proteins.Selinexor is the first generation XPO1 inhibitor.At present,selinexor has gained more attention in the application of multiple myeloma(MM).Meanwhile,the latest clinical trials have confirmed that whether it is a single agent or combined with other chemotherapy regimens,selinexor can also achieve good therapeutic effects in patients with leukemia and lymphoma.This review summarizes the results of preclinical studies and clinical trials of selinexor in treatment of non-MM hematological malignancies,aiming to explore how to choose single agent or in combination with other regimens as induction chemotherapy.
